Showing results (31-40 of 39) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Revue Neurologique|January 7, 2023
Cerebrospinal fluid biomarkers in SARS-CoV-2 patients with acute neurological syndromesH Chaumont, F Kaczorowski, A San-Galli, et al.Biometals : an International Journal on the Role of Metal Ions in Biology, Biochemistry, and Medicine|October 27, 2015
Piperazine derivatives as iron chelators: a potential application in neurobiologyS Abdelsayed, N T Ha Duong, C Bureau, et al.Journal of Neurochemistry|March 22, 2001
Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease?A Hartmann, P P Michel, J D Troadec, et al.Proceedings of the National Academy of Sciences of the United States of America|July 8, 1997
Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson diseaseS Hunot, B Brugg, D Ricard, et al.Revue Neurologique|July 31, 1998
[Neuronal death caused by apoptosis in Parkinson disease]M Ruberg, V France-Lanord, B Brugg, et al.Histology and Histopathology|January 1, 1997
Apoptosis and autophagy in nigral neurons of patients with Parkinson's diseaseP Anglade, S Vyas, F Javoy-Agid, et al.Neuroscience|October 3, 2003
The mitochondrial complex I inhibitor annonacin is toxic to mesencephalic dopaminergic neurons by impairment of energy metabolismA Lannuzel, P P Michel, G U Höglinger, et al.Proceedings of the National Academy of Sciences of the United States of America|February 26, 2000
Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's diseaseA Hartmann, S Hunot, P P Michel, et al.Movement Disorders : Official Journal of the Movement Disorder Society|September 17, 2004
Levodopa in the treatment of Parkinson's disease: current controversiesC Warren Olanow, Yves Agid, Yoshi Mizuno, et al.Pageof 4